{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:26:06Z","timestamp":1793993166986,"version":"4.8.0"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100020152","name":"Madrigal Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK120515"],"award-info":[{"award-number":["P30DK120515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Resmetirom is an oral thyroid hormone receptor beta agonist clinically used to treat metabolic dysfunction\u2010associated steatohepatitis (MASH) among adults with stage F2 or F3 fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Because the pivotal, 52\u2010week, randomized, controlled, phase 3 MAESTRO\u2010NASH trial (once\u2010daily oral resmetirom 80 or 100\u2009mg or placebo) included patients with F1, F2, or F3 fibrosis, we conducted a post hoc analysis aimed at assessing treatment response in the subset of patients with stages F2 and F3 fibrosis, consistent with the approved label population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Co\u2010primary end points were MASH resolution (hepatocellular ballooning score 0, lobular inflammation score \u2264\u20091, and \u2265\u20092\u2010point nonalcoholic fatty liver disease activity score [NAS] reduction from baseline) with no fibrosis worsening, and \u2265\u20091\u2010stage fibrosis improvement with no NAS worsening at Week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 917 patients with F2 or F3 fibrosis, metabolic risk factor prevalence was high (hypertension, 78.0%; dyslipidemia, 71.1%; type 2 diabetes, 67.0%). MASH resolution was achieved by 25.7% in the 80\u2010mg group, 29.9% in the 100\u2010mg group, and 9.5% in the placebo group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 for both comparisons with placebo). Respective percentages with fibrosis improvement were 26.5%, 28.9%, and 17.3% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01 for both comparisons). From baseline to Week 24, low\u2010density lipoprotein cholesterol decreased by 11.7% and 13.7% in the 80\u2010 and 100\u2010mg resmetirom groups, respectively, and increased by 2.3% with placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 for both comparisons). No new safety signals emerged.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results among patients with F2 and F3 fibrosis were consistent with the primary MAESTRO\u2010NASH analysis population, demonstrating efficacy and safety of resmetirom after 52\u2009weeks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.70888","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:06:57Z","timestamp":1785380817000},"page":"919-929","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction\u2010Associated Steatohepatitis\u2014Reanalysis of Fibrosis Stage 2\u20133 Subset"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-097X","authenticated-orcid":false,"given":"Maria","family":"Mironova","sequence":"first","affiliation":[{"name":"MASLD Research Center, Division of Gastroenterology and Hepatology University of California at San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Padmanabhan","sequence":"additional","affiliation":[{"name":"Madrigal Pharmaceuticals, Inc.  West Conshohocken Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schneider","sequence":"additional","affiliation":[{"name":"Madrigal Pharmaceuticals, Inc.  West Conshohocken Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine II Saarland University Medical Center  Homburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[{"name":"MASLD Research Center, Division of Gastroenterology and Hepatology University of California at San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00599-1"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14825"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28785"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0651"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29085"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029349"},{"key":"e_1_2_10_12_1","unstructured":"Rezdiffra [prescribing information] \u201cMadrigal Pharmaceuticals \u201d(2024)."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00260-2"},{"key":"e_1_2_10_14_1","unstructured":"Rezdiffra [summary of product characteristics] \u201cMadrigal Pharmaceuticals \u201d(2025)."},{"key":"e_1_2_10_15_1","unstructured":"S. O.Omokaro \u201cFDA Regulatory Considerations for NASH Clinical Trial Endpoints. Presented at: Global NASH Congress \u201d2018."},{"key":"e_1_2_10_16_1","unstructured":"US Food and Drug Administration \u201cNoncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment \u201d(2026) https:\/\/www.fda.gov\/media\/119044\/download."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01858.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.005"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e328332dd0a"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02603-1"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.70888","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.70888","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.70888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:43:17Z","timestamp":1793990597000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.70888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/apt.70888"],"URL":"https:\/\/doi.org\/10.1111\/apt.70888","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"2026-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}